Insulin detemir. A second long-acting insulin analogue: Many uncertainties, few advantages

Prescrire International

Volumn 15, Issue 85, 2006, Pages 163-167

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; DRUG DERIVATIVE; INSULIN;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; EUROPE; GLYCEMIC CONTROL; HUMAN; HYPOALBUMINEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREGNANCY; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; EUROPE; HUMANS; INSULIN; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33749331569     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Prescrire Editorial Staff "Type I diabetes: benefits of intensive insulin therapy" Prescrire Int 2001; 10 (58): 61.
2. Prescrire Editorial Staff "Insulin in type 2 diabetes" Prescrire Int 2005; 14 (79): 187-193.
3. Prescrire Rédaction "Insulines: quoi de neuf en 2005?" Rev Prescrire 2005; 25 (262): 428-429.
4. o. Premier analogue de l'insuline à action prolongée" Rev Prescrire 2005; 25 (261): 325-332.
5. Prescrire Rédaction "Effets indésirables des analogues de l'insuline: rester vigilant sur le long-terme" Rev Prescrire 2005; 25 (261): 328.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-536. Clinical pharmacology and biopharmaceuticals review" 13 May 2005: 67 pages.
7. European Medicines Agency - CHMP "European Public Assessment Report (Rev. 2) - Levemir. Scientific discussion": 29 pages posted on the EMEA website on 21 September 2005.
8. Commission de la transparence "Avis de la Commission - Levemir 100 U/ ml" 30 March 2005: 19 pages.
9. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-536. Medical review" 9 June 2005: 82 pages.
10. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-536. Statistical review" 13 May 2005: 61 pages.
11. Novo Nordisk "Insulin detemir. Clinical overview" 24 October 2002: 43 pages.
12. U.S. Food and Drug Administration, "Final printed labeling for approved NDA 21-878" 19 October 2005: 15 pages.
13. Home P et al. "Insulin detemir offers improved glycemic control compared with NPH insulin in people with type I diabetes" Diabetes Care 2004; 27 (5): 1081-1087 + (letter) 27 (10): 2567-2568.
14. Russel-Jones D et al. "Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen" Clin Ther 2004, 26 (5): 724-736.
15. Kolendorf K et al. "Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with type 1 diabetes" Diabetologia 2004; 47 (suppl. 1) (abstr. 913): 1 page.
16. Haak T et al. "Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes" Diabetes Obes Metab 2005; 7: 56-64.
17. Prescrire Rédaction "Une démarche pour éviter les effets indésirables par interactions médicamenteuses" Rev Prescrire 2006; 26 (270 suppl.): 6-8.
18. Gamson K et al. "The safety and efficacy of insulin analogs in pregnancy" J Mater Fetal Neonatal Med 2004; 15: 26-34.
19. Agarwal MM and Punnose J "Recent advances in the treatment of gestational diabetes" Exp Opin Invest Drug 2004; 13 (9): 1103-1111.
20. Prescrire Rédaction "Arrêts de commercialisation" Rev Prescrire 2005; 25 (265): 664.